About: Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
Creator	Ibáñez, Sebastián Valenzuela, Omar Silva, Francisco Valenzuela, Francisca Martínez, Oriela
Source	Medline; PMC
abstract	The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.1007/s10067-020-05202-4
bibo:pmid	32495226
has license	no-cc
sha1sum (hex)	6e8c3d60557415ff0eb9817d7f3e990b5f7d9050
schema:url	https://doi.org/10.1007/s10067-020-05202-4
resource representing a document's title	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
has PubMed Central identifier	PMC7267470
has PubMed identifier	32495226
schema:publication	Clin Rheumatol
resource representing a document's body	covid:6e8c3d60557415ff0eb9817d7f3e990b5f7d9050#body_text
is schema:about of	named entity 'Hydroxychloroquine' named entity 'drugs' named entity 'COVID-19' named entity 'objective' named entity 'medications' named entity 'hospitalizations' named entity 'oxygen therapy' named entity 'chloroquine' named entity 'coronavirus' named entity 'dendritic cells' named entity 'QT interval prolongation' named entity 'standard of care' named entity 'bacterial infection' named entity 'virus' named entity 'U937 cells' named entity 'HIV' named entity 'standard of care' named entity 'retrospective study' named entity 'antimalarials' named entity 'malaria' named entity 'virus' named entity 'viral RNA' named entity 'open-label' named entity 'ACE2' named entity 'p38' named entity 'viral antigens' named entity 'COVID-19' named entity 'cardiovascular' named entity 'HCQ' named entity 'Mechanisms of action' named entity 'biosynthesis' named entity 'kinases' named entity 'mechanism of action' named entity 'slow down the spread' named entity 'HCQ' named entity 'anecdotal evidence' named entity 'COVID-19' named entity 'electrocardiogram' named entity 'tumor necrosis factor-alpha' named entity 'hypertension' named entity 'treatment group' named entity 'HCQ' named entity 'ICU' named entity 'controlled study' named entity 'cardiovascular events' named entity 'virus' named entity 'immune response' named entity 'autophagosome' named entity 'HCQ' named entity 'IFNγ' named entity 'HCQ' named entity 'antiviral effect' named entity 'PCR' named entity 'ceftriaxone' named entity 'open-label' named entity 'virus' named entity 'antibiotics' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'COVID' named entity 'antimalarials' named entity 'mechanism of action' named entity 'orthomyxoviruses' named entity 'interferon-alpha' named entity 'primary endpoint' named entity 'anti-inflammatory response' named entity 'HCQ' named entity 'IL-1' named entity 'IFNβ' named entity 'health care systems' named entity 'virus' named entity 'volume of distribution' named entity 'mechanism of action' named entity 'THP-1' named entity 'SARS-CoV-2' named entity 'cough' named entity 'patient-centered outcomes' named entity 'immune cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software